SEC Form 3 · accession 0001209191-18-022389

CHIASMA, INC · CHMA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — See Remarks

Period of report

Mar 22, 2018

Accepted (ET)

Apr 2, 2018 · 4:36 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001339469

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	holding	—	—		—	5,124	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F1	$28.40	holding	—	—	—	—	Sep 10, 2025	Common Stock	14,084	—	D
Stock Option (Right to Buy)^F1	$28.40	holding	—	—	—	—	Sep 10, 2025	Common Stock	45,916	—	D
Stock Option (Right to Buy)^F2	$9.93	holding	—	—	—	—	Feb 10, 2026	Common Stock	969	—	D
Stock Option (Right to Buy)^F2	$9.93	holding	—	—	—	—	Feb 10, 2026	Common Stock	14,531	—	D
Stock Option (Right to Buy)^F3	$2.60	holding	—	—	—	—	Oct 25, 2026	Common Stock	25,003	—	D
Stock Option (Right to Buy)^F3	$2.60	holding	—	—	—	—	Oct 25, 2026	Common Stock	74,997	—	D
Stock Option (Right to Buy)^F4	$1.52	holding	—	—	—	—	Feb 23, 2028	Common Stock	52,011	—	D
Stock Option (Right to Buy)^F5	$1.52	holding	—	—	—	—	Feb 23, 2028	Common Stock	18,189	—	D

F1This option vests over a four-year period at a rate of twenty-five percent (25%) on August 26, 2016 and 36 equal monthly installments thereafter.
F2This option vests over a four-year period at a rate of twenty-five percent (25%) on February 10, 2017 and in 12 equal quarterly installments thereafter.
F3This option vests over a four-year period at a rate of twenty-five percent (25%) on October 25, 2017 and in 12 equal quarterly installments thereafter.
F4This option vests over a four-year period in 16 equal quarterly installments, the first such installment vesting on May 23, 2018.
F5This option vests as follows: (i) 40% of such award will be earned upon FDA acceptance of a new drug application ("NDA") for Mycapssa, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such acceptance; and (ii) 60% of such award will be earned upon FDA approval of such NDA, of which amount 50% will be immediately vested and 50% will vest upon the one year anniversary of such approval.

Title: Senior Vice President, Clinical and Medical Affairs